Technical Analysis for VTYX - Ventyx Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 3.93 | -3.20% | -0.13 |
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Narrow Range Bar | Range Contraction | -3.20% | |
| Wide Bands | Range Expansion | -3.20% | |
| Oversold Stochastic | Weakness | -3.20% | |
| Outside Day | Range Expansion | -7.31% | |
| Wide Bands | Range Expansion | -7.31% | |
| Oversold Stochastic | Weakness | -7.31% |
| Alert | Time |
|---|---|
| Down 3% | about 9 hours ago |
| Fell Below Previous Day's Low | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 9 hours ago |
| Possible NR7 | about 10 hours ago |
| Possible Inside Day | about 10 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/09/2024
Ventyx Biosciences, Inc. Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Autoimmune Disease Inflammatory Diseases Psoriasis Inflammatory Bowel Disease Ulcerative Colitis Autoimmune Disorders Cytokine Lupus Immune Mediated Diseases Molecule Product Psoriatic Arthritis Inflammasome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 40.5785 |
| 52 Week Low | 1.865 |
| Average Volume | 4,580,264 |
| 200-Day Moving Average | 14.44 |
| 50-Day Moving Average | 6.03 |
| 20-Day Moving Average | 4.65 |
| 10-Day Moving Average | 4.35 |
| Average True Range | 0.42 |
| RSI (14) | 31.03 |
| ADX | 24.12 |
| +DI | 15.33 |
| -DI | 28.15 |
| Chandelier Exit (Long, 3 ATRs) | 4.81 |
| Chandelier Exit (Short, 3 ATRs) | 5.18 |
| Upper Bollinger Bands | 5.45 |
| Lower Bollinger Band | 3.84 |
| Percent B (%b) | 0.05 |
| BandWidth | 34.62 |
| MACD Line | -0.52 |
| MACD Signal Line | -0.49 |
| MACD Histogram | -0.0309 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.16 | ||||
| Resistance 3 (R3) | 4.19 | 4.13 | 4.12 | ||
| Resistance 2 (R2) | 4.13 | 4.07 | 4.12 | 4.11 | |
| Resistance 1 (R1) | 4.03 | 4.04 | 4.01 | 4.01 | 4.10 |
| Pivot Point | 3.98 | 3.98 | 3.97 | 3.97 | 3.98 |
| Support 1 (S1) | 3.88 | 3.92 | 3.85 | 3.85 | 3.76 |
| Support 2 (S2) | 3.82 | 3.88 | 3.81 | 3.75 | |
| Support 3 (S3) | 3.72 | 3.82 | 3.74 | ||
| Support 4 (S4) | 3.70 |
